See more : Ibersol, S.G.P.S., S.A. (IBS.LS) Income Statement Analysis – Financial Results
Complete financial analysis of EyePoint Pharmaceuticals, Inc. (EYPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EyePoint Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Luenmei Quantum Co.,Ltd (600167.SS) Income Statement Analysis – Financial Results
- Chosun Refractories Co.,Ltd. (000480.KS) Income Statement Analysis – Financial Results
- MediPal Holdings Corporation (MAHLY) Income Statement Analysis – Financial Results
- Matrix Service Company (MTRX) Income Statement Analysis – Financial Results
- Vertical Exploration Inc. (VERT.V) Income Statement Analysis – Financial Results
EyePoint Pharmaceuticals, Inc. (EYPT)
About EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.02M | 41.40M | 36.94M | 34.44M | 20.37M | 2.96M | 7.54M | 1.62M | 26.57M | 3.47M | 2.14M | 3.53M | 4.97M | 23.05M | 12.16M | 3.48M | 2.24M | 1.47M | 629.52K | 265.23K | 74.35K | 516.32K |
| Cost of Revenue | 4.63M | 8.33M | 8.18M | 5.82M | 2.69M | 18.50M | 0.00 | 815.00K | 14.38M | 78.00K | 9.57M | 7.01M | 7.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 41.39M | 33.08M | 28.76M | 28.61M | 17.68M | -15.54M | 7.54M | 805.00K | 12.18M | 3.40M | -7.43M | -3.48M | -2.07M | 23.05M | 12.16M | 3.48M | 2.24M | 1.47M | 629.52K | 265.23K | 74.35K | 516.32K |
| Gross Profit Ratio | 89.93% | 79.89% | 77.86% | 83.09% | 86.81% | -524.86% | 100.00% | 49.69% | 45.86% | 97.75% | -346.71% | -98.67% | -41.77% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 64.66M | 49.64M | 28.50M | 17.42M | 15.37M | 16.18M | 14.88M | 14.38M | 12.09M | 9.57M | 7.01M | 7.04M | 6.86M | 6.99M | 8.01M | 14.43M | 20.03M | 11.70M | 6.29M | 4.87M | 3.08M | 1.80M |
| General & Administrative | 40.10M | 34.82M | 25.58M | 20.73M | 17.94M | 11.55M | 11.24M | 9.01M | 8.06M | 7.47M | 7.17M | 6.87M | 8.10M | 6.97M | 8.79M | 13.95M | 13.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 11.69M | 25.51M | 27.50M | 25.29M | 29.77M | 1.51M | 1.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -969.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 51.79M | 60.32M | 53.08M | 46.02M | 47.71M | 13.06M | 11.24M | 9.01M | 8.06M | 7.47M | 7.17M | 6.87M | 8.10M | 6.97M | 8.79M | 13.95M | 12.98M | 15.88M | 3.81M | 1.60M | 565.51K | 0.00 |
| Other Expenses | 0.00 | 2.05M | 2.46M | 2.46M | 2.46M | 14.84M | 8.31M | 13.98M | 3.00K | 7.26M | 6.23M | 19.79M | 3.25M | 3.25M | 0.00 | 71.20M | 4.77M | 1.56M | 781.71K | 27.35K | 25.42K | 0.00 |
| Operating Expenses | 115.05M | 112.02M | 84.04M | 65.90M | 65.54M | 29.24M | 26.12M | 23.39M | 20.14M | 17.04M | 14.17M | 13.91M | 14.97M | 13.96M | 16.80M | 28.38M | 37.78M | 29.14M | 10.88M | 6.50M | 3.67M | 1.80M |
| Cost & Expenses | 121.09M | 120.34M | 92.22M | 71.73M | 68.23M | 29.24M | 26.12M | 23.39M | 20.14M | 17.04M | 14.17M | 13.91M | 14.97M | 13.96M | 16.80M | 28.38M | 37.78M | 29.14M | 10.88M | 6.50M | 3.67M | 1.80M |
| Interest Income | 6.95M | 2.13M | 292.00K | 58.00K | 1.05M | 101.00K | 91.00K | 72.00K | 19.00K | 6.00K | 16.00K | 38.00K | 30.00K | 27.00K | 162.00K | 648.00K | 300.00K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.25M | 3.19M | 5.50M | 7.26M | 6.18M | 720.00K | 720.00K | 0.00 | 0.00 | 1.00K | 2.00K | 0.00 | 1.00K | 13.00K | 0.00 | 507.00K | 1.94M | 3.37M | 3.37M | 3.92K | 3.92K | 0.00 |
| Depreciation & Amortization | 464.00K | 2.45M | 2.77M | 2.65M | 2.60M | 2.65M | 815.00K | 815.00K | 882.00K | 917.00K | 994.00K | 2.23M | 3.36M | 3.33M | 3.44M | 397.00K | 8.72M | 8.70M | 1.24M | 240.94K | 212.09K | 516.32K |
| EBITDA | -69.00M | -96.62M | -50.15M | -35.49M | -48.01M | -36.99M | -18.58M | -17.67M | -20.87M | 7.30M | -12.65M | -11.04M | -22.78M | -5.49M | 9.09M | -24.00K | -75.65M | -22.05M | -18.98M | -9.44M | -6.00M | -3.39M |
| EBITDA Ratio | -149.94% | -180.56% | -142.19% | -100.97% | -217.76% | -883.92% | -246.40% | -1,344.07% | 24.17% | -364.09% | -560.66% | 121.38% | -224.17% | 40.92% | -8.52% | 773.56% | 2,814.09% | -1,504.38% | -1,235.68% | -2,643.41% | -4,552.30% | -247.68% |
| Operating Income | -75.07M | -78.94M | -55.28M | -37.29M | -47.86M | -26.27M | -18.58M | -21.77M | 6.42M | -13.49M | -12.03M | -25.21M | -10.00M | 9.09M | -4.64M | -24.90M | -35.54M | -27.68M | -10.25M | -6.24M | -3.60M | -1.80M |
| Operating Income Ratio | -163.13% | -190.65% | -149.64% | -108.28% | -235.02% | -887.34% | -246.40% | -1,344.07% | 24.17% | -388.42% | -561.41% | -715.00% | -201.47% | 39.44% | -38.12% | -716.37% | -1,590.25% | -1,888.63% | -1,628.79% | -2,351.37% | -4,838.64% | -347.68% |
| Total Other Income/Expenses | 4.36M | -2.62M | -3.14M | -8.10M | -8.93M | -63.17M | -26.90M | 91.00K | 72.00K | 22.00K | 5.00K | 14.00K | 207.00K | 1.16M | -315.00K | 1.17M | 8.85M | -61.21M | -17.73M | 9.32M | -807.00 | -1.80M |
| Income Before Tax | -70.71M | -102.25M | -58.42M | -45.39M | -56.79M | -53.17M | -18.49M | -21.70M | 6.44M | -13.49M | -12.02M | -25.00M | -8.85M | 8.78M | -3.46M | -76.15M | -127.20M | -27.98M | -11.49M | -5.22M | -3.60M | -2.25M |
| Income Before Tax Ratio | -153.66% | -246.97% | -158.14% | -131.82% | -278.88% | -1,795.71% | -245.19% | -1,339.63% | 24.25% | -388.28% | -560.76% | -709.13% | -178.17% | 38.07% | -28.47% | -2,190.82% | -5,691.41% | -1,909.47% | -1,824.63% | -1,969.97% | -4,839.72% | -436.07% |
| Income Tax Expense | 83.00K | 22.26M | 5.50M | 7.26M | 6.18M | -25.56M | -815.00K | -155.00K | 96.00K | -130.00K | -117.00K | -169.00K | -218.00K | 23.00K | -951.00K | -483.00K | -23.53M | -7.07M | -303.15K | -2.67M | -1.74M | -1.80M |
| Net Income | -70.80M | -124.51M | -63.92M | -52.65M | -62.97M | -53.17M | -18.49M | -21.55M | 6.35M | -13.36M | -11.90M | -24.84M | -8.63M | 8.75M | -2.51M | -75.67M | -103.68M | -20.91M | -11.18M | -2.56M | -1.86M | -2.25M |
| Net Income Ratio | -153.84% | -300.72% | -173.03% | -152.89% | -309.20% | -1,795.71% | -245.19% | -1,330.06% | 23.89% | -384.54% | -555.30% | -704.34% | -173.78% | 37.97% | -20.65% | -2,176.93% | -4,638.70% | -1,427.12% | -1,776.47% | -965.00% | -2,498.46% | -436.07% |
| EPS | -1.82 | -3.34 | -2.22 | -4.10 | -6.04 | -11.50 | -5.23 | -6.81 | 2.16 | -4.87 | -5.16 | -11.95 | -4.43 | 4.76 | -1.37 | -41.65 | -93.93 | -27.81 | -21.53 | -0.84 | -7.32 | -5.48 |
| EPS Diluted | -1.82 | -3.34 | -2.22 | -4.10 | -6.04 | -11.50 | -5.23 | -6.81 | 2.08 | -4.87 | -5.16 | -11.95 | -4.43 | 4.63 | -1.37 | -41.65 | -93.93 | -27.81 | -21.53 | -2.08 | -7.32 | -5.48 |
| Weighted Avg Shares Out | 38.90M | 37.32M | 28.76M | 12.84M | 10.43M | 4.62M | 3.53M | 3.16M | 2.94M | 2.74M | 2.30M | 2.08M | 1.95M | 1.84M | 1.83M | 1.82M | 1.10M | 752.10K | 519.50K | 3.06M | 253.65K | 410.92K |
| Weighted Avg Shares Out (Dil) | 38.90M | 37.32M | 28.76M | 12.84M | 10.43M | 4.62M | 3.53M | 3.16M | 3.06M | 2.74M | 2.30M | 2.08M | 1.95M | 1.89M | 1.83M | 1.82M | 1.10M | 752.10K | 519.50K | 1.23M | 253.65K | 410.92K |
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
– Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients...
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety, and efficacy, and reduced treatment burden, positioning it as...
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
The mean of analysts' price targets for EyePoint Pharmaceuticals (EYPT) points to a 175.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.33 per share a year ago.
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at...
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the closing of its previously announced...
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public...
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten...
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema
- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline -
Source: https://incomestatements.info
Category: Stock Reports